Completed NA INTERVENTIONAL 2-arm NCT01901458

Two Different Collection Sets for Peripheral Blood Progenitor Cell Apheresis With Spectra Optia® (optiMaL)

Prospective Randomized Trial Comparing Efficiency of Peripheral Blood Progenitor Cell Collection in Allogeneic Donors Using the Spectra Optia® IDL Set in Comparison With the Spectra Optia® MNC Collection Set

Sponsor: Chugai Pharma USA

Conditions Granulocyte Colony-stimulating Factor (G-CSF) Mobilized Healthy Allogeneic Donors

Interventions Spectra Optia® Collection Set Spectra Optia® IDL-Set

Updated 6 times since 2017 Last updated: Mar 18, 2015 Started: Mar 31, 2014 Primary completion: Nov 30, 2014 Completion: Nov 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Granulocyte Colony-stimulating Factor (G-CSF) Mobilized and Healthy Allogeneic Donors, this trial is completed. The trial is conducted by Chugai Pharma USA and has accumulated 6 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chugai Pharma USA
Heinrich-Heine University, Duesseldorf
Terumo BCT

Data source: Heinrich-Heine University, Duesseldorf

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cologne, Germany
• Düsseldorf, Germany